TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| BioDelivery Sciences, Antigenics, Cel-Sci All Look Like Winners VFC submits: These three stocks have rebounded nicely on Monday, bouncing off recent lows and an uptrend is in order for each of these stocks. For BioDelivery Sciences (BDSI), the company is a long term keeper now, in my opinion, and the stock price will eventually reflect that fact - post-Onsolis-approval price action aside.Complete Story » seekingalpha.com |
Johnston Health to build $60M hospital in Clayton CLAYTON – Johnston County hospital leaders are putting the finishing touches on a plan that would deliver a $60 million, full-service hospital to the growing community of Clayton. feeds.bizjournals.com |
New Gripe on Health-Care Bill Hospitals and insurers are pushing back against changes to a Senate bill that ease penalties for not carrying health insurance. online.barrons.com |
EXACT Sciences: Buy and Hold for Long-Term Upside Mike Havrilla submits:EXACT Sciences (NASDAQ: EXAS) is a molecular diagnostics company that is developing a next-generation (V3), stool DNA (sDNA) based screening test for colorectal cancer (CRC) which has demonstrated the ability to detect both early-stage cancer and pre-cancerous growths. The company's sDNA-based screening technology platform has also demonstrated the ability to detect related GI cancers and pre-cancers.Only 24% of an estimated 90 million individuals in the U.S. are currently compliant with CRC screening recommendations, which results in an estimated 68 million people who are non-compliant. The early detection of CRC saves both lives and money by avoiding the high costs of dealing with late-stage disease through expensive anti-cancer drugs and/or palliative care. Late stage (III/IV) CRC accounts for 60% of diagnoses, but the five-year survival rates for Stage III CRC is 60% and just 11% for Stage IV disease. Compare those statistics to early stage disease, which includes a 90% five-year survival rate for Stage I CRC and 70% for Stage II.Complete Story » seekingalpha.com |
Enzo Biochem 1Q loss narrows on revenue boost (AP) Biotechnology company Enzo Biochem Inc. said Thursday its 2010 fiscal first-quarter loss narrowed on a boost in laboratory services and product revenue. us.rd.yahoo.com |